EPRX · Eupraxia Pharmaceuticals Inc
United States · RS rating 53 · As of 2026-11-03
| Price | 6.88 USD |
|---|---|
| 1-day change | +1.8% |
| RS rating (overall / 1M / 3M / 12M) | 53 / 33 / 77 / 71 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 28 / 33 / 23 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +24.4% |
| Market cap (USD) | $445.9M |